| NCT — Nicastrin | |
|---|---|
| Symbol | NCT |
| Full Name | Nicastrin |
| Chromosome | 1p31.3 |
| NCBI Gene | 51594 |
| Ensembl | ENSG00000103546 |
| UniProt | Q92542 |
| Primary Disease Links | [Alzheimer's disease](/diseases/alzheimers), [Parkinson's disease](/diseases/parkinsons-disease) |
Nct (Nicastrin) Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
NCT encodes nicastrin, a core membrane glycoprotein of the gamma-secretase complex. Nicastrin is required for stable assembly and trafficking of Presenilin-1 (PSEN1), Presenilin-2 (PSEN2), APH1, and PEN2, and it helps position transmembrane substrates for intramembrane cleavage.[1][2] In neurons and glia, this complex processes many signaling proteins, most prominently APP, where cleavage balance influences generation of amyloid-beta peptides relevant to Alzheimer's disease pathogenesis.[3][4]
The human gene resides on chromosome 1p31.3 and encodes a type I transmembrane glycoprotein with a large ectodomain. Structural work shows nicastrin does not function as a classical protease; instead it acts as a scaffolded substrate-gating partner that contributes to substrate recruitment and quality control of complex assembly.[1:1][5] Glycosylation of the ectodomain is important for maturation and endosomal-lysosomal trafficking of the active complex, linking nicastrin biology to broader autophagy-lysosomal pathways.[6]
Gamma-secretase activity depends on correct stoichiometric assembly of all four subunits. Nicastrin promotes maturation of presenilin holoprotein into catalytically active N- and C-terminal fragments and supports transport of assembled complex from ER/Golgi compartments to endosomes and plasma membrane microdomains.[2:1][6:1] Because APP and Notch are both gamma-secretase substrates, NCT influences neuronal proteostasis and cell-fate signaling in parallel.[7]
In APP processing, altered gamma-secretase processivity can shift peptide length distributions, including pathogenic Aβ42 enrichment. Nicastrin state (expression, glycoforms, subcellular localization) modifies this processivity context with presenilin variants, creating an interaction layer between genetic background and amyloid output.[3:1][4:1][8]
NCT itself is not a common high-penetrance Mendelian AD gene, but convergent human genetic and biochemical data support it as a modifier in amyloidogenic pathways. Experimental reduction of nicastrin expression decreases overall gamma-secretase activity and lowers Aβ generation, while risking mechanism-based toxicity from impaired Notch signaling if inhibition is not substrate-selective.[7:1][8:1] This helped motivate the field shift from broad gamma-secretase inhibitors to modulators that tune cleavage pattern rather than fully block catalytic activity.[9]
Nicastrin is also linked to microglial and astrocytic biology indirectly through APP fragment signaling and inflammatory feed-forward pathways engaging NF-kappaB. In AD tissue and models, this axis may couple amyloid burden to chronic glial activation.[10]
Although strongest evidence centers on AD, gamma-secretase substrates also include proteins relevant to synaptic maintenance and axonal function in Parkinson's disease and frontotemporal dementia. Dysregulated membrane protein cleavage can perturb endolysosomal flux and mitochondrial stress signaling, pathways repeatedly implicated across PD, DLB, and atypical parkinsonism.[6:2][11] This positions NCT as a cross-disease systems node rather than a disease-specific driver gene.
Current therapeutic logic emphasizes substrate-selective modulation of gamma-secretase or pathway-level combination strategies (for example, pairing amyloid-targeted biologics with upstream processing modulators). NCT biology is central to both strategies because it influences complex stability, substrate presentation, and compartment-specific cleavage behavior.[8:2][9:1] Open translational questions include whether cell-type-selective delivery or context-dependent modulation can reduce Aβ toxicity without Notch-related adverse effects.
The study of Nct (Nicastrin) Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Shah S, Lee SF, Tabuchi K, et al. Nicastrin functions as a gamma-secretase-substrate receptor. Cell. 2005. ↩︎ ↩︎
Kaether C, Haass C, Steiner H. Assembly, trafficking and function of gamma-secretase. Nat Rev Neurosci. 2006. ↩︎ ↩︎
Selkoe DJ, Hardy J. [The amyloid hypothesis of Alzheimer's disease at 25 years](https://doi.org/10.1016/S0092-8674(16). Cell. 2016. ↩︎ ↩︎
Szaruga M, Veugelen S, Benurwar M, et al. Alzheimer's-causing mutations shift Aβ length by destabilizing gamma-secretase-Aβn interactions. Cell. 2017. ↩︎ ↩︎
Zhou R, Yang G, Guo X, et al. Recognition of APP C99 by the active gamma-secretase complex. Science. 2019. ↩︎
Sannerud R, Declerck I, Peric A, et al. Restricted location of PSEN2/gamma-secretase determines substrate specificity and generates an intracellular Aβ pool. Cell. 2016. ↩︎ ↩︎ ↩︎
De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and gamma-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb Perspect Med. 2012. ↩︎ ↩︎
Chávez-Gutiérrez L, Bammens L, Benilova I, et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. Nat Neurosci. 2012. ↩︎ ↩︎ ↩︎
Rynearson KD, Ponnusamy M, Prikhodko O, et al. Preclinical validation of a potent gamma-secretase modulator for Alzheimer's disease prevention. Proc Natl Acad Sci U S A. 2018. ↩︎ ↩︎
Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014. ↩︎
Moors T, Paciotti S, Chiasserini D, et al. Lysosomal dysfunction and alpha-synuclein aggregation in Parkinson's disease. Mov Disord. 2017. ↩︎